How do I buy Teva Pharmaceuticals (TEVA) stock?

Buying Teva Pharmaceuticals (TEVA) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "TEVA", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy TEVA by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if TEVA is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Teva Pharmaceuticals (TEVA) Stock

Q: What is the minimum investment for TEVA on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Teva Pharmaceuticals from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NEW YORK STOCK EXCHANGE, INC. · TEVA

Trade TEVA

Key stats

Market cap: $48.75B
Price / Earnings ratio: 96.5x
EPS (TTM): $0.45
Volume: Loading
52-week high: $43.34
52-week low: $22.70
EPS vs analyst estimate: +16.4%Q3 FY25 · $0.78 vs $0.67

Source: third-party data provider, as of November 7, 2026

EPS estimate: analyst consensus

Compare with TEVA

Technical indicators

RSI 14: 58.59
MACD 12/26/9: 0.61
EMA 9 of MACD: 0.57
MACD histogram: 0.04
SMA 50: $39.40; Price above SMA 50
EMA 50: $39.45; Price above EMA 50
SMA 200: $34.78; Price above SMA 200
EMA 200: $35.09; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 7 analyst ratings

Strong Sell0

Sell0

Hold0

Buy7

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

21B14B7B0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

57B38B19B0

Revenue to Profit

2025

$17.3B

Revenue

$0.0

Cost of revenue

$8.9B

Gross profit

$0.0

Operating expenses

$1.4B

Net income

Earnings

EPS forecast

Actual EPS

$0.78

$0.67

Q3FY25

$0.64

Q4FY25

$0.57

Q1FY26

$0.62

Q2FY26

$0.69

Q3FY26

The market is expecting earnings per share of $0.69 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Teva Pharmaceuticals

In a complex world, Teva's mission is simple: to be a global leader in genetics and biopharmaceuticals, improving the lives of patients across the world. We believe that everyone should have access to quality medicines whether it be for managing disease, fighting infections, or simply improving overall health. We are proud that since Teva’s establishment in 1901, healthcare providers together with patients and caregivers have been using our accessible generic and innovative products. Today, our portfolio is among the largest of any pharmaceutical company in the world. We invest in research and development of generic medicines and biopharmaceuticals, carrying on the legacy of more than a century of finding new ways to help patients improve their lives.

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees31,173

CEOMr. Richard D. Francis

IPO DateMar 26, 1990

HeadquartersTel Aviv-Yafo, Israel

Key Executives

Name	Title	Year Born
Mr. Richard D. Francis	President, CEO & Director	1968
Mr. Eliyahu Sharon Kalif	Executive VP & CFO	1974
Dr. Eric A. Hughes M.D., Ph.D.	Executive VP of Global R&D and Chief Medical Officer	1970
Ms. Christine Fox	Executive VP of US Commercial & Head of Innovative Franchise	1969
Mr. Evan Lippman M.B.A.	Executive Vice President of Business Development	1970
Mr. Matthew Shields	Executive Vice President of Global Operations	1975
Mr. Amir Weiss	Senior VP & Chief Accounting Officer	1977
Mr. Christopher J. Stevo CFA	Senior Vice President of Investor Relations & Competitive Intelligence	—
Kathleen Veit	Senior Vice President, Global Compliance & Ethics Officer	—
Mr. Brian Savage	Interim Chief Legal Officer	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-11.5	-2.1
2022	+1.2	-6.7	+20.5	-7.2	+6.7	-19.4	+18.9	-4.6	-9.6	+8.4	-3.8	+4.8
2023	+10.6	-6.5	-12.2	-4.3	-18.6	+4.6	+12.3	+17.7	+3.7	-14.3	+12.1	+7.5
2024	+13.4	+5.5	+4.5	+1.0	+21.1	-4.3	+6.7	+7.6	-2.7	+4.4	-9.1	+32.4
2025	-16.8	-5.1	-3.9	+1.4	+7.4	-2.9	-7.2	+19.5	+7.7	+2.1	+31.0	+16.8
2026	+10.1	-4.7	-10.8	+15.9	+1.1	-2.2	+4.7	+4.6	+9.4	+7.1	+2.7

Stocks in the same sector

Amneal Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc

ANIP

ANI Pharmaceuticals Inc

FAQ

Buying Teva Pharmaceuticals (TEVA) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "TEVA", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy TEVA by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Teva Pharmaceuticals from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Teva Pharmaceuticals (TEVA) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track TEVA's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Teva Pharmaceuticals (TEVA) Stock

Key stats

Compare with TEVA

Recent news

Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Key Metrics

Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Key Metrics

Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo

Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo

Teva Pharma Jumps As Top 6% Pharma Raises Outlook After Quarterly Beat

Teva Pharma Jumps As Top 6% Pharma Raises Outlook After Quarterly Beat

Teva Pharmaceutical Q3 profit gain beats estimates

Teva Pharmaceutical Q3 profit gain beats estimates

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Key Metrics

Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Key Metrics

Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo

Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo

Teva Pharma Jumps As Top 6% Pharma Raises Outlook After Quarterly Beat

Teva Pharma Jumps As Top 6% Pharma Raises Outlook After Quarterly Beat

Teva Pharmaceutical Q3 profit gain beats estimates

Teva Pharmaceutical Q3 profit gain beats estimates

Teva to discontinue mid-stage neurodegenerative disorder study

Teva to discontinue mid-stage neurodegenerative disorder study

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking

Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?

Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?

What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings

What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

TEVA Stock Hits Fresh 52-Week High As FDA Approves Monthly Schizophrenia Shot

TEVA Stock Hits Fresh 52-Week High As FDA Approves Monthly Schizophrenia Shot

About Teva Pharmaceuticals

Key Executives

Fundamentals

Valuation

Profitability

Trading

Dividend

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade